Targeting p53 in the Treatment of Hematologic Malignancies With Matthew Davids, MD, MMSc
Keira Smith
Expert Analysis
Matthew Davids, MD, MMSc. Tumor suppressor gene p53 is the most frequently mutated gene in human malignancy. Through a complex series of molecular events, p53 leads to malignant cell proliferation and plays a significant role in tumor formation. In the Presidential Symposium at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Dr. Matthew Davids of Harvard Medical School discussed the current therapeutic strategies used to inhibit or reactivate mutant p53 in the treatment of hematologic malignancies. In this interview with Oncology Data Advisor, Dr. Davids delves further into the latest research in p53-directed therapeutic strategies and the future of targeting this specific mutation.  
The Call to Understand Racial and Socioeconomic Disparities in Pediatric Acute Lymphoblastic Leukemia: Sumit Gupta, MD
Keira Smith
Expert Analysis
Although survival in childhood acute lymphoblastic leukemia (ALL) has improved over the years, there remains a need to identify racial, ethnic, and socioeconomic health disparities that contribute to poor outcomes. In a study recently presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, a team of researchers l...
The Burden of Myelosuppressive Hematologic Adverse Events in Small Cell Lung Cancer: Jerome Goldschmidt, MD
Keira Smith
Expert Analysis
For patients with extensive-stage small cell lung cancer (SCLC), cytotoxic chemotherapy remains a mainstay of treatment. However, myelosuppressive hematologic adverse events such as anemia, neutropenia, and thrombocytopenia pose a significant challenge to care. In a study recently presented at the 63rd American Society of Hematology (ASH) Annual Me...
Lisocabtagene Maraleucel and the Transforming Treatment Landscape for Large B-Cell Lymphoma: Manali Kamdar, MD
Keira Smith
Expert Analysis
For patients with relapsed/refractory large B-cell lymphoma (LBCL), treatment options are limited, and outcomes remain poor with the current standard of care. In the phase 3 TRANSFORM trial, Dr. Manali Kamdar, Clinical Director of Lymphoma Services at the University of Colorado Anschutz School of Medicine, and colleagues investigated the efficacy o...
Reducing Racial and Ethnic Disparities in Clinical Trial Enrollment for Acute Lymphoblastic Leukemia: Lori Muffly, MD, MS
Keira Smith
Expert Analysis
Compared with the non-Hispanic White population, Hispanic and Black adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) experience significantly inferior outcomes. In an analysis of the CALGB 10403 AYA trial presented at the recent American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, ...
Addressing Racial Disparities in Clinical Trial Recruitment: Alexis A. Thompson, MD, MPH
Keira Smith
Expert Analysis
One of the issues surrounding hematology care is the underrepresentation of racial and ethnic minorities in clinical trials. At the recent 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Alexis A. Thompson, MD, MPH, past President of ASH and Professor of Pediatrics at Northwestern University's Feinberg...
Axicabtagene Ciloleucel and Increasing Accessibility to CAR T-Cell Therapy With Frederick Locke, MD
Keira Smith
Expert Analysis
While the current standard of care for relapsed/refractory large B-cell lymphoma is high-dose therapy with autologous stem cell rescue, many patients do not respond to or cannot tolerate high-dose therapy. As a result, outcomes for second-line treatment remain poor. At the recent American Society of Hematology (ASH) 63rd Annual Meeting & Exposi...
Polatuzumab Vedotin Plus R-CHP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: John Burke, MD
Keira Smith
Expert Analysis
For patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), less than half of patients are cured with the current standard of care, and effective treatments are greatly needed. In the phase 3 POLARIX trial, a team of researchers investigated the efficacy of polatuzumab vedotin in combination with R-CHP (rituximab/cyclophosphamide/doxor...
Duvelisib/Romidepsin for Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma: Steven M. Horwitz, MD
Keira Smith
Expert Analysis
For patients with relapsed/refractory T-cell lymphoma (TCL), standard therapies provide an overall response rate of only 25% to 35%, and novel therapeutic options are greatly needed. In a study recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. St...
Pevonedistat Plus Azacitidine for Patients With Higher-Risk MDS, CMML, and AML: Mikkael A. Sekeres, MD
Keira Smith
Expert Analysis
For older patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML) with 20% to 30% marrow blasts, treatment options are limited. In the PANTHER study, the results of which were recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting & Exposition...
CARG Chemotherapy Toxicity Calculator Found Not Valid for Older Patients With Hematologic Malignancies: Ashley Rosko, MD
Keira Smith
Expert Analysis
Understanding the balance between effective treatments and health-related quality of life is crucial, especially when treating older adults with hematologic malignancies. The Cancer and Aging Research Group (CARG) chemotherapy toxicity calculator has been sufficiently studied and utilized in patients with solid tumors; however, its efficacy in the ...
Safely Reducing Patient Hospital Stay After CAR T-Cell Therapy: Remote Patient Monitoring With Morie Gertz, MD
Keira Smith
Expert Analysis
While chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment landscape for patients with hematologic malignancies, challenges remain in the management of short-term toxicities, most notably cytokine release syndrome and neurologic symptoms. In nearly all cases to date, optimal management has only been achieved through in...
i3 Health Publishes T-Cell Lymphoma Education Study in American Society of Hematology Online Program
Keira Smith
Press
i3 Health's study focusing on the effectiveness of an online continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity to improve clinicians' knowledge of therapeutic advances in T-cell lymphoma (TCL) has been published as a 63rd American Society of Hematology (ASH) Annual Meeting & Exposition online abstract. 

Copyright © 2022 Oncology Data Advisor. All rights reserved.